Mice carrying a hypomorphic Evi1 allele are embryonic viable but exhibit severe congenital heart defects

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Bard Chapeau, Emilie A ^a   Szumska, Dorota ^b   Jacob, Bindya ^c   Chua, Belinda Q L ^a   Chatterjee, Gouri C ^d   Zhang, Yi ^e   Ward, Jerrold M ^a   Urun, Fatma ^f   Kinameri, Emi ^f   Vincent, Stéphane D ^g   Ahmed, Sayadi ^a   Bhattacharya, Shoumo ^b   Osato, Motomi ^c   Perkins, Archibald S ^e   Moore, Adrian W ^f   Jenkins, Nancy A ^a,h   Copeland, Neal G ^a,h  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^g UNIVERSITÉ DE STRASBOURG   (France)

^h HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALLELE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; DISEASE SEVERITY; EMBRYO; EMBRYO DEVELOPMENT; EVI1 GENE; EXON; GENE DELETION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE SILENCING; GENE TARGETING; GERM LINE; HEMATOPOIETIC CELL; HETEROZYGOTE; LETHALITY; MOUSE; NEWBORN; NONHUMAN; PERINATAL PERIOD; PHENOTYPE; REGULATOR GENE; TRANSCRIPTION INITIATION SITE;

ALLELES; ANIMALS; ANIMALS, NEWBORN; BASE SEQUENCE; BONE MARROW; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; EXONS; GENE DELETION; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENES, LETHAL; GENETIC ASSOCIATION STUDIES; HEART DEFECTS, CONGENITAL; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; IMMUNOPHENOTYPING; MICE; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; MUTATION; PHENOTYPE; PROTO-ONCOGENES; SEQUENCE ALIGNMENT; SEVERITY OF ILLNESS INDEX; TRANSCRIPTION FACTORS;

EID: 84897883757     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089397     Document Type: Article

References (89)

1. Koonin EV, Wolf YI (2010) Constraints and plasticity in genome and molecularphenome evolution. Nat Rev Genet 11: 487-498.
2. Nerlov C (2010) Transcriptional and translational control of C/EBPs: the case for ''deep'' genetics to understand physiological function. Bioessays 32: 680-686.
3. Lugthart S, van Drunen E, van Norden Y, van Hoven A, Erpelinck CA, et al. (2008) High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 111: 4329-4337.
4. Ogawa S, Kurokawa M, Tanaka T, Mitani K, Inazawa J, et al. (1996) Structurally altered Evi-1 protein generated in the 3q21q26 syndrome. Oncogene 13: 183-191. (Pubitemid 26248559)
5. Goyama S, Kurokawa M (2009) Pathogenetic significance of ecotropic viral integration site-1 in hematological malignancies. Cancer Sci 100: 990-995.
6. Bei JX, Li Y, Jia WH, Feng BJ, Zhou G, et al. (2010) A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet 42: 599-603.
7. Brooks DJ, Woodward S, Thompson FH, Dos Santos B, Russell M, et al. (1996) Expression of the zinc finger gene EVI-1 in ovarian and other cancers. Br J Cancer 74: 1518-1525. (Pubitemid 26386076)
8. Choi YW, Choi JS, Zheng LT, Lim YJ, Yoon HK, et al. (2007) Comparative genomic hybridization array analysis and real time PCR reveals genomic alterations in squamous cell carcinomas of the lung. Lung Cancer 55: 43-51. (Pubitemid 46038877)
9. Koos B, Bender S, Witt H, Mertsch S, Felsberg J, et al. (2011) The transcription factor Evi-1 is overexpressed, promotes proliferation and is prognostically unfavorable in infratentorial ependymomas. Clin Cancer Res.
10. Starr TK, Allaei R, Silverstein KA, Staggs RA, Sarver AL, et al. (2009) A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science 323: 1747-1750.
11. Yokoi S, Yasui K, Iizasa T, Imoto I, Fujisawa T, et al. (2003) TERC identified as a probable target within the 3q26 amplicon that is detected frequently in nonsmall cell lung cancers. Clin Cancer Res 9: 4705-4713. (Pubitemid 37323272)
12. Goyama S, Yamamoto G, Shimabe M, Sato T, Ichikawa M, et al. (2008) Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 3: 207-220.
13. Yuasa H, Oike Y, Iwama A, Nishikata I, Sugiyama D, et al. (2005) Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J 24: 1976-1987. (Pubitemid 40896169)
14. Nucifora G, Laricchia-Robbio L, Senyuk V (2006) EVI1 and hematopoietic disorders: history and perspectives. Gene 368: 1-11. (Pubitemid 43290136)
15. Goyama S, Kurokawa M (2010) Evi-1 as a critical regulator of leukemic cells. Int J Hematol 91: 753-757.
16. Bard-Chapeau EA, Jeyakani J, Kok CH, Muller J, Chua BQ, et al. (2012) Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors. Proc Natl Acad Sci U S A 109: 2168-2173.
17. Delwel R, Funabiki T, Kreider BL, Morishita K, Ihle JN (1993) Four of the seven zinc fingers of the Evi-1 myeloid-transforming gene are required for sequence-specific binding to GA(C/T)AAGA(T/C)AAGATAA. Mol Cell Biol 13: 4291-4300. (Pubitemid 23187658)
18. Perkins AS, Fishel R, Jenkins NA, Copeland NG (1991) Evi-1, a murine zinc finger proto-oncogene, encodes a sequence-specific DNA-binding protein. Mol Cell Biol 11: 2665-2674. (Pubitemid 21895646)
19. Yatsula B, Lin S, Read AJ, Poholek A, Yates K, et al. (2005) Identification of binding sites of EVI1 in mammalian cells. J Biol Chem 280: 30712-30722. (Pubitemid 41291800)
20. Funabiki T, Kreider BL, Ihle JN (1994) The carboxyl domain of zinc fingers of the Evi-1 myeloid transforming gene binds a consensus sequence of GAAGATGAG. Oncogene 9: 1575-1581. (Pubitemid 24163382)
21. Zhang Y, Stehling-Sun S, Lezon-Geyda K, Juneja SC, Coillard L, et al. (2011) PR-domain-containing Mds1-Evi1 is critical for long-term hematopoietic stem cell function. Blood 118: 3853-3861.
22. Hohenauer T, Moore AW (2012) The Prdm family: expanding roles in stem cells and development. Development 139: 2267-2282.
23. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, van der Poel-van de Luytgaarde S, et al. (2003) High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 101: 837-845.
24. Nanjundan M, Nakayama Y, Cheng KW, Lahad J, Liu J, et al. (2007) Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res 67: 3074-3084. (Pubitemid 46724844)
25. Sood R, Talwar-Trikha A, Chakrabarti SR, Nucifora G (1999) MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1. Leukemia 13: 348-357. (Pubitemid 29108073)
26. Bartholomew C, Clark AM (1994) Induction of two alternatively spliced evi-1 proto-oncogene transcripts by cAMP in kidney cells. Oncogene 9: 939-942. (Pubitemid 24065934)
27. Bordereaux D, Fichelson S, Tambourin P, Gisselbrecht S (1990) Alternative splicing of the Evi-1 zinc finger gene generates mRNAs which differ by the number of zinc finger motifs. Oncogene 5: 925-927.
28. Morishita K, Parganas E, Parham DM, Matsugi T, Ihle JN (1990) The Evi-1 zinc finger myeloid transforming gene is normally expressed in the kidney and in developing oocytes. Oncogene 5: 1419-1423.
29. Hoyt PR, Bartholomew C, Davis AJ, Yutzey K, Gamer LW, et al. (1997) The Evi1 proto-oncogene is required at midgestation for neural, heart, and paraxial mesenchyme development. Mech Dev 65: 55-70. (Pubitemid 27314591)
30. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108. (Pubitemid 351818697)
31. Bard-Chapeau EA, Hevener AL, Long S, Zhang EE, Olefsky JM, et al. (2005) Deletion of Gab1 in the liver leads to enhanced glucose tolerance and improved hepatic insulin action. Nat Med 11: 567-571. (Pubitemid 40685981)
32. Yamashita N, Osato M, Huang L, Yanagida M, Kogan SC, et al. (2005) Haploinsufficiency of Runx1/AML1 promotes myeloid features and leukaemogenesis in BXH2 mice. Br J Haematol 131: 495-507. (Pubitemid 43899649)
33. Schneider JE, Bose J, Bamforth SD, Gruber AD, Broadbent C, et al. (2004) Identification of cardiac malformations in mice lacking Ptdsr using a novel high-throughput magnetic resonance imaging technique. BMC Dev Biol 4: 16.
34. Szumska D, Pieles G, Essalmani R, Bilski M, Mesnard D, et al. (2008) VACTERL/caudal regression/Currarino syndrome-like malformations in mice with mutation in the proprotein convertase Pcsk5. Genes Dev 22: 1465-1477. (Pubitemid 351793081)
35. Palmer S, Brouillet JP, Kilbey A, Fulton R, Walker M, et al. (2001) Evi-1 transforming and repressor activities are mediated by CtBP co-repressor proteins. J Biol Chem 276: 25834-25840.
36. Kinameri E, Inoue T, Aruga J, Imayoshi I, Kageyama R, et al. (2008) Prdm proto-oncogene transcription factor family expression and interaction with the Notch-Hes pathway in mouse neurogenesis. PLoS One 3: e3859.
37. Alzuherri H, McGilvray R, Kilbey A, Bartholomew C (2006) Conservation and expression of a novel alternatively spliced Evi1 exon. Gene 384: 154-162. (Pubitemid 44738335)
38. Harhay GP, Sonstegard TS, Keele JW, Heaton MP, Clawson ML, et al. (2005) Characterization of 954 bovine full-CDS cDNA sequences. BMC Genomics 6: 166.
39. Ware J, Russell S, Ruggeri ZM (2000) Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc Natl Acad Sci U S A 97: 2803-2808. (Pubitemid 30159252)
40. Ogilvy S, Elefanty AG, Visvader J, Bath ML, Harris AW, et al. (1998) Transcriptional regulation of vav, a gene expressed throughout the hematopoietic compartment. Blood 91: 419-430. (Pubitemid 28053363)
41. MacDonald ST, Bamforth SD, Chen CM, Farthing CR, Franklyn A, et al. (2008) Epiblastic Cited2 deficiency results in cardiac phenotypic heterogeneity and provides a mechanism for haploinsufficiency. Cardiovasc Res 79: 448-457.
42. Conway SJ, Kruzynska-Frejtag A, Kneer PL, Machnicki M, Koushik SV (2003) What cardiovascular defect does my prenatal mouse mutant have, and why? Genesis 35: 1-21. (Pubitemid 36150977)
43. Vincent SD, Buckingham ME (2010) How to make a heart: the origin and regulation of cardiac progenitor cells. Curr Top Dev Biol 90: 1-41.
44. Blake JA, Bult CJ, Kadin JA, Richardson JE, Eppig JT (2011) The Mouse Genome Database (MGD): premier model organism resource for mammalian genomics and genetics. Nucleic Acids Res 39: D842-848.
45. Bentham J, Bhattacharya S (2008) Genetic mechanisms controlling cardiovascular development. Ann N Y Acad Sci 1123: 10-19. (Pubitemid 351431299)
46. Bard-Chapeau EA, Gunaratne J, Kumar P, Chua BQ, Muller J, et al. (2013) EVI1 oncoprotein interacts with a large and complex network of proteins and integrates signals through protein phosphorylation. Proc Natl Acad Sci U S A 110: E2885-2894.
47. Kurokawa M, Ogawa S, Tanaka T, Mitani K, Yazaki Y, et al. (1995) The AML1/Evi-1 fusion protein in the t(3;21) translocation exhibits transforming activity on Rat1 fibroblasts with dependence on the Evi-1 sequence. Oncogene 11: 833-840.
48. Mitani K (2004) Molecular mechanisms of leukemogenesis by AML1/EVI-1. Oncogene 23: 4263-4269.
49. Ogawa S, Kurokawa M, Tanaka T, Tanaka K, Hangaishi A, et al. (1996) Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia. Leukemia 10: 788-794. (Pubitemid 26168395)
50. Tanaka T, Nishida J, Mitani K, Ogawa S, Yazaki Y, et al. (1994) Evi-1 raises AP-1 activity and stimulates c-fos promoter transactivation with dependence on the second zinc finger domain. J Biol Chem 269: 24020-24026. (Pubitemid 24300933)
51. Boyd KE, Xiao YY, Fan K, Poholek A, Copeland NG, et al. (2006) Sox4 cooperates with Evi1 in AKXD-23 myeloid tumors via transactivation of proviral LTR. Blood 107: 733-741. (Pubitemid 43076400)
52. Modlich U, Schambach A, Brugman MH, Wicke DC, Knoess S, et al. (2008) Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia 22: 1519-1528.
53. Metais JY, Dunbar CE (2008) The MDS1-EVI1 gene complex as a retrovirus integration site: impact on behavior of hematopoietic cells and implications for gene therapy. Mol Ther 16: 439-449.
54. Wieser R (2007) The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Gene 396: 346-357.
55. Morrison SJ, Uchida N, Weissman IL (1995) The biology of hematopoietic stem cells. Annu Rev Cell Dev Biol 11: 35-71. (Pubitemid 26019601)
56. Weskamp G, Cai H, Brodie TA, Higashyama S, Manova K, et al. (2002) Mice lacking the metalloprotease-disintegrin MDC9 (ADAM9) have no evident major abnormalities during development or adult life. Mol Cell Biol 22: 1537-1544. (Pubitemid 34150789)
57. Horiuchi K, Zhou HM, Kelly K, Manova K, Blobel CP (2005) Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins beta1 and beta2. Dev Biol 283: 459-471. (Pubitemid 40977963)
58. Liu W, Selever J, Wang D, Lu MF, Moses KA, et al. (2004) Bmp4 signaling is required for outflow-tract septation and branchial-arch artery remodeling. Proc Natl Acad Sci U S A 101: 4489-4494. (Pubitemid 38437438)
59. Beppu H, Malhotra R, Beppu Y, Lepore JJ, Parmacek MS, et al. (2009) BMP type II receptor regulates positioning of outflow tract and remodeling of atrioventricular cushion during cardiogenesis. Dev Biol 331: 167-175.
60. Danesh SM, Villasenor A, Chong D, Soukup C, Cleaver O (2009) BMP and BMP receptor expression during murine organogenesis. Gene Expr Patterns 9: 255-265.
61. Cohen AW, Park DS, Woodman SE, Williams TM, Chandra M, et al. (2003) Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. Am J Physiol Cell Physiol 284: C457-474. (Pubitemid 36120083)
62. Sanlaville D, Etchevers HC, Gonzales M, Martinovic J, Clement-Ziza M, et al. (2006) Phenotypic spectrum of CHARGE syndrome in fetuses with CHD7 truncating mutations correlates with expression during human development. J Med Genet 43: 211-217.
63. Weninger WJ, Lopes Floro K, Bennett MB, Withington SL, Preis JI, et al. (2005) Cited2 is required both for heart morphogenesis and establishment of the leftright axis in mouse development. Development 132: 1337-1348. (Pubitemid 40528793)
64. Lopes Floro K, Artap ST, Preis JI, Fatkin D, Chapman G, et al. (2011) Loss of Cited2 causes congenital heart disease by perturbing left-right patterning of the body axis. Hum Mol Genet 20: 1097-1110.
65. Guris DL, Fantes J, Tara D, Druker BJ, Imamoto A (2001) Mice lacking the homologue of the human 22q11.2 gene CRKL phenocopy neurocristopathies of DiGeorge syndrome. Nat Genet 27: 293-298. (Pubitemid 32201850)
66. Tissir F, Wang CE, Goffinet AM (2004) Expression of the chemokine receptor Cxcr4 mRNA during mouse brain development. Brain Res Dev Brain Res 149: 63-71. (Pubitemid 38315063)
67. Norris RA, Moreno-Rodriguez R, Wessels A, Merot J, Bruneval P, et al. (2010) Expression of the familial cardiac valvular dystrophy gene, filamin-A, during heart morphogenesis. Dev Dyn 239: 2118-2127.
68. Wang B, Weidenfeld J, Lu MM, Maika S, Kuziel WA, et al. (2004) Foxp1 regulates cardiac outflow tract, endocardial cushion morphogenesis and myocyte proliferation and maturation. Development 131: 4477-4487. (Pubitemid 39409689)
69. Brewer AC, Alexandrovich A, Mjaatvedt CH, Shah AM, Patient RK, et al. (2005) GATA factors lie upstream of Nkx 2.5 in the transcriptional regulatory cascade that effects cardiogenesis. Stem Cells Dev 14: 425-439. (Pubitemid 41244834)
70. Lepore JJ, Mericko PA, Cheng L, Lu MM, Morrisey EE, et al. (2006) GATA-6 regulates semaphorin 3C and is required in cardiac neural crest for cardiovascular morphogenesis. J Clin Invest 116: 929-939.
71. Fischer A, Steidl C, Wagner TU, Lang E, Jakob PM, et al. (2007) Combined loss of Hey1 and HeyL causes congenital heart defects because of impaired epithelial to mesenchymal transition. Circ Res 100: 856-863. (Pubitemid 46555691)
72. Nakagawa O, Nakagawa M, Richardson JA, Olson EN, Srivastava D (1999) HRT1, HRT2, and HRT3: a new subclass of bHLH transcription factors marking specific cardiac, somitic, and pharyngeal arch segments. Dev Biol 216: 72-84.
73. Leimeister C, Externbrink A, Klamt B, Gessler M (1999) Hey genes: a novel subfamily of hairy- and Enhancer of split related genes specifically expressed during mouse embryogenesis. Mech Dev 85: 173-177. (Pubitemid 29343761)
74. Loomes KM, Underkoffler LA, Morabito J, Gottlieb S, Piccoli DA, et al. (1999) The expression of Jagged1 in the developing mammalian heart correlates with cardiovascular disease in Alagille syndrome. Hum Mol Genet 8: 2443-2449.
75. Zhang T, Liu J, Zhang J, Thekkethottiyil EB, Macatee TL, et al. (2013) Jun is required in Isl1-expressing progenitor cells for cardiovascular development. PLoS One 8: e57032.
76. Baek ST, Tallquist MD (2012) Nf1 limits epicardial derivative expansion by regulating epithelial to mesenchymal transition and proliferation. Development 139: 2040-2049.
77. Gammill LS, Gonzalez C, Bronner-Fraser M (2007) Neuropilin 2/semaphorin 3F signaling is essential for cranial neural crest migration and trigeminal ganglion condensation. Dev Neurobiol 67: 47-56. (Pubitemid 46146139)
78. Gammill LS, Gonzalez C, Gu C, Bronner-Fraser M (2006) Guidance of trunk neural crest migration requires neuropilin 2/semaphorin 3F signaling. Development 133: 99-106. (Pubitemid 43169324)
79. Lee MK, Slunt HH, Martin LJ, Thinakaran G, Kim G, et al. (1996) Expression of presenilin 1 and 2 (PS1 and PS2) in human and murine tissues. J Neurosci 16: 7513-7525. (Pubitemid 26389690)
80. Nakajima M, Moriizumi E, Koseki H, Shirasawa T (2004) Presenilin 1 is essential for cardiac morphogenesis. Dev Dyn 230: 795-799. (Pubitemid 38993879)
81. Mollard R, Viville S, Ward SJ, Decimo D, Chambon P, et al. (2000) Tissue-specific expression of retinoic acid receptor isoform transcripts in the mouse embryo. Mech Dev 94: 223-232. (Pubitemid 30332406)
82. Dolle P, Fraulob V, Kastner P, Chambon P (1994) Developmental expression of murine retinoid X receptor (RXR) genes. Mech Dev 45: 91-104. (Pubitemid 24061356)
83. Ya J, Schilham MW, de Boer PA, Moorman AF, Clevers H, et al. (1998) Sox4-deficiency syndrome in mice is an animal model for common trunk. Circ Res 83: 986-994. (Pubitemid 28520928)
84. Roelen BA, Lin HY, Knezevic V, Freund E, Mummery CL (1994) Expression of TGF-beta s and their receptors during implantation and organogenesis of the mouse embryo. Dev Biol 166: 716-728.
85. Wang YQ, Sizeland A, Wang XF, Sassoon D (1995) Restricted expression of type-II TGF beta receptor in murine embryonic development suggests a central role in tissue modeling and CNS patterning. Mech Dev 52: 275-289.
86. Mariano JM, Montuenga LM, Prentice MA, Cuttitta F, Jakowlew SB (1998) Concurrent and distinct transcription and translation of transforming growth factor-beta type I and type II receptors in rodent embryogenesis. Int J Dev Biol 42: 1125-1136. (Pubitemid 28561894)
87. Iruela-Arispe ML, Liska DJ, Sage EH, Bornstein P (1993) Differential expression of thrombospondin 1, 2, and 3 during murine development. Dev Dyn 197: 40-56. (Pubitemid 23254781)
88. Bentham J, Bhattacharya S (2008) Genetic mechanisms controlling cardiovascular development. Ann N Y Acad Sci 1123: 10-19. (Pubitemid 351431299)
89. Bard-Chapeau EA, Jeyakani J, Kok CH, Muller J, Chua BQ, et al. (2012) Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors. Proc Natl Acad Sci U S A 109: 2168-2173.